Skip to main content

Table 2 Clinical and laboratory features of two groups

From: A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India

  PQ high dose (N = 25) n (%) or Mean ± SD or Median (IQR) PQ low dose (N = 25) n (%) or Mean ± SD or Median (IQR) p-value
Fever 25 (100) 25 (100)  
Splenomegaly 3 (12) 2 (8) 0.63
Hepatomegaly 2 (8) 2 (8) 1.00
Haemoglobin, gm/dl 13.2 ± 1.7 13.5 ± 1.7 0.45
Urea, mg/dl 33.3 ± 19.9 31.7 ± 13.4 0.43
Creatinine, mg/dl 1.2 ± 0.4 1.1 ± 0.4 0.36
Total bilirubin, mg/dl 1.4 (1.3, 1.9) 1.5 (0.95, 3.0) 0.36
Direct bilirubin, mg/dl 0.6 (0.3, 0.8) 0.6 (0.3, 1.4) 0.12
Aspartate amino transferase, IU/l 39.5 (35.5, 54.0) 30.0 (27.0, 41.0) 0.38
Alanine amino transferase, IU/l 40.5 (29.0, 67.0) 34.0 (24.0, 44.0) 0.67
Alkaline phosphatase, IU/l 87.0 (62.5, 118.5) 82.0 (57.0, 110.0) 0.34
PQ concentration (µg/ml) (N = 30) 0.576 (0.186, 0.782) 0.184 (0.131, 0.282) 0.193
Carboxy PQ concentration (µg/ml) (N = 30) 2.401 (1.535, 4.119) 2.809 (0.817, 6.658) 0.945